Markets:

Overview

News

Currencies

International

Treasuries

VanEck Pharmaceutical ETF (NQ:PPH)

115.55 -1.73 (-1.48%)

Streaming Delayed Price Updated: 3:21 PM EDT, Aug 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about VanEck Pharmaceutical ETF

< Previous 1 2 3 Next >

Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? ↗

August 18, 2026

PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.

Via The Motley Fool

Topics ETFs

PPH vs. IYH: Which Healthcare Fund Is the Better Buy? ↗

August 18, 2026

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.

Via The Motley Fool

Topics ETFs

VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗

August 12, 2026

VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.

Via The Motley Fool

Topics ETFs

Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report ↗

February 12, 2026

Via Stocktwits

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show? ↗

January 30, 2026

Via Stocktwits

Why Did NRXP Stock Surge 21% Pre-Market Today? ↗

January 14, 2026

Via Stocktwits

Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio? ↗

July 26, 2026

PPH targets drugmakers exclusively with higher returns but steeper costs, while XLV diversifies across medical equipment and providers at a fraction of the fee.

Via The Motley Fool

Topics ETFs

Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ ↗

July 23, 2026

The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The...

Via The Motley Fool

Topics ETFs

For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? ↗

July 20, 2026

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

Via The Motley Fool

Topics ETFs

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? ↗

July 09, 2026

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

Via The Motley Fool

Topics ETFs

Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? ↗

July 04, 2026

Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.

Via The Motley Fool

Topics ETFs

Vanguard (VHT) vs VanEck (PPH): Which Healthcare ETF Is the Better Buy? ↗

June 18, 2026

Broader diversification or higher yield? Explore how these two healthcare ETFs stack up for different investor goals.

Via The Motley Fool

Topics ETFs

Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns. ↗

June 02, 2026

Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.

Via The Motley Fool

Topics ETFs

PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem ↗

May 27, 2026

A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles.

Via The Motley Fool

Topics ETFs

Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock ↗

March 10, 2026

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

Via Stocktwits

Topics Intellectual Property Lawsuit

HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy ↗

March 09, 2026

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

Via Stocktwits

Topics Intellectual Property Lawsuit

FDA Vaccine Chief Vinay Prasad To Exit Agency In April: Report ↗

March 06, 2026

The Wall Street Journal reported the upcoming departure on Friday, citing FDA Commissioner Marty Makary.

Via Stocktwits

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗

February 25, 2026

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

Via Stocktwits

Why Did GERN Stock Tumble 10% Pre-Market Today? ↗

February 25, 2026

Total revenue reached $48 million for the fourth-quarter with a loss per share (EPS) of $0.05, with both metrics coming in below street estimates.

Via Stocktwits

Topics Artificial Intelligence

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report ↗

February 24, 2026

According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027.

Via Stocktwits

Topics Artificial Intelligence

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China ↗

February 24, 2026

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

Via Stocktwits

Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗

February 23, 2026

According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.

Via Stocktwits

Topics Intellectual Property

Why Is NVO Stock Falling Pre-Market Today? ↗

February 23, 2026

The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.

Via Stocktwits

Topics Government

FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains ↗

February 09, 2026

According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy.

Via Stocktwits

Topics Lawsuit

Why Did IINN Stock Surge 28% In Pre-Market Today? ↗

February 09, 2026

The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.

Via Stocktwits

Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks ↗

February 09, 2026

Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.

Via Stocktwits

Topics Intellectual Property Lawsuit

US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗

December 01, 2025

The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.

Via Stocktwits

Topics World Trade

Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗

November 17, 2025

With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation.

Via Benzinga

Topics ETFs

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs ↗

November 15, 2025

A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.

Via Benzinga

Topics ETFs

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗

November 12, 2025

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.